The evolution of a migraine attack - A review of recent evidence

Headache

Volumn 53, Issue 2, 2013, Pages 413-419

  Charles, Andrew ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

aura; headache; magnetic resonance imaging; positron emission tomography; postdrome; premonitory

Indexed keywords

2' METHOXYPHENYL ( N 2' PYRIDINYL) 4 FLUOROBENZAMIDOETHYLPIPERAZINE F 18; CALCITONIN GENE RELATED PEPTIDE; DOMPERIDONE; DOPAMINE; DOPAMINE RECEPTOR STIMULATING AGENT; GLYCERYL TRINITRATE; HYPOPHYSIS ADENYLATE CYCLASE ACTIVATING POLYPEPTIDE; LASMIDITAN; NITRIC OXIDE; PIPERAZINE DERIVATIVE; PROSTACYCLIN; PROSTAGLANDIN E2; PROSTANOID; SEROTONIN 1B AGONIST; SEROTONIN AGONIST; SEROTONIN D RECEPTOR AGONIST; SEROTONIN F RECEPTOR AGONIST; SEROTONIN RECEPTOR; SILDENAFIL; SUMATRIPTAN; TRIPTAN DERIVATIVE; UNCLASSIFIED DRUG;

BRAIN BLOOD FLOW; BRAIN CORTEX; BRAIN FUNCTION; BRAIN REGION; CLINICAL OBSERVATION; CLINICAL TRIAL (TOPIC); COMPUTER ASSISTED TOMOGRAPHY; DIZZINESS; DRUG EFFICACY; DRUG SAFETY; EVIDENCE BASED MEDICINE; EVOKED RESPONSE; FATIGUE; HEADACHE; HUMAN; HYPOTHALAMUS; MEDIATOR; MIGRAINE; MIGRAINE ATTACK; MIGRAINE AURA; MIGRAINE WITH AURA; MIGRAINE WITHOUT AURA; NEUROANATOMY; NEUROCHEMISTRY; NEUROIMAGING; NEUROPATHOLOGY; NOCICEPTION; NUCLEAR MAGNETIC RESONANCE IMAGING; PATHOPHYSIOLOGY; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; REVIEW; RISK FACTOR; SENSITIZATION; SENSORY STIMULATION; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; SPREADING CORTICAL DEPRESSION; SYMPTOM; TEMPORAL CORTEX; THALAMUS; TRANSCRANIAL MAGNETIC STIMULATION; VERTIGO;

HUMANS; MAGNETIC RESONANCE IMAGING; MIGRAINE DISORDERS; POSITRON-EMISSION TOMOGRAPHY;

EID: 84874429443     PISSN: 00178748     EISSN: 15264610     Source Type: Journal    
DOI: 10.1111/head.12026     Document Type: Review

References (74)

1. Waelkens J,. Warning symptoms in migraine: Characteristics and therapeutic implications. Cephalalgia. 1985; 5: 223-228.
2. Becker WJ,. The premonitory phase of migraine and migraine management. Cephalalgia. 2012; Epub DOI 10.1177/0333102412437390.
3. Cuvellier JC, Mars A, Vallee L,. The prevalence of premonitory symptoms in paediatric migraine: A questionnaire study in 103 children and adolescents. Cephalalgia. 2009; 29: 1197-1201.
4. Giffin NJ, Ruggiero L, Lipton RB, et al. Premonitory symptoms in migraine: An electronic diary study. Neurology. 2003; 60: 935-940.
5. Kelman L,. The premonitory symptoms (prodrome): A tertiary care study of 893 migraineurs. Headache. 2004; 44: 865-872.
6. Quintela E, Castillo J, Munoz P, Pascual J,. Premonitory and resolution symptoms in migraine: A prospective study in 100 unselected patients. Cephalalgia. 2006; 26: 1051-1060.
7. Schoonman GG, Evers DJ, Terwindt GM, van, Dijk JG, Ferrari MD,. The prevalence of premonitory symptoms in migraine: A questionnaire study in 461 patients. Cephalalgia. 2006; 26: 1209-1213.
8. Kelman L,. The postdrome of the acute migraine attack. Cephalalgia. 2006; 26: 214-220.
9. Ng-Mak DS, Fitzgerald KA, Norquist JM, et al. Key concepts of migraine postdrome: A qualitative study to develop a post-migraine questionnaire. Headache. 2011; 51: 105-117.
10. Akerman S, Goadsby PJ,. Dopamine and migraine: Biology and clinical implications. Cephalalgia. 2007; 27: 1308-1314.
11. Cerbo R, Barbanti P, Buzzi MG, et al. Dopamine hypersensitivity in migraine: Role of the apomorphine test. Clin Neuropharmacol. 1997; 20: 36-41.
12. Fanciullacci M, Alessandri M, Del Rosso A,. Dopamine involvement in the migraine attack. Funct Neurol. 2000; 15 (Suppl. 3): 171-181.
13. Peroutka SJ,. Dopamine and migraine. Neurology. 1997; 49: 650-656.
14. Blin O, Azulay JP, Masson G, Aubrespy G, Serratrice G,. Apomorphine-induced yawning in migraine patients: Enhanced responsiveness. Clin Neuropharmacol. 1991; 14: 91-95.
15. Patatanian E, Williams NT,. Drug-induced yawning-a review. Ann Pharmacother. 2011; 45: 1297-1301.
16. Waelkens J,. Dopamine blockade with domperidone: Bridge between prophylactic and abortive treatment of migraine? A dose-finding study. Cephalalgia. 1984; 4: 85-90.
17. Friedman BW, Esses D, Solorzano C, et al. A randomized controlled trial of prochlorperazine versus metoclopramide for treatment of acute migraine. Ann Emerg Med. 2008; 52: 399-406.
18. Friedman BW, Mulvey L, Esses D, et al. Metoclopramide for acute migraine: A dose-finding randomized clinical trial. Ann Emerg Med. 2011; 57: 475-482 e471.
19. Tfelt-Hansen P, Henry P, Mulder LJ, Scheldewaert RG, Schoenen J, Chazot G,. The effectiveness of combined oral lysine acetylsalicylate and metoclopramide compared with oral sumatriptan for migraine. Lancet. 1995; 346: 923-926.
20. Alstadhaug KB,. Migraine and the hypothalamus. Cephalalgia. 2009; 29: 809-817.
21. Judit A, Sandor PS, Schoenen J,. Habituation of visual and intensity dependence of auditory evoked cortical potentials tends to normalize just before and during the migraine attack. Cephalalgia. 2000; 20: 714-719.
22. Denuelle M, Fabre N, Payoux F, Chollet Gilles G,. Hypothalamic activation in spontaneous migraine attacks. Headache. 2007; 47: 1418-1426.
23. Afridi SK, Kaube H, Goadsby PJ,. Glyceryl trinitrate triggers premonitory symptoms in migraineurs. Pain. 2004; 110: 675-680.
24. 15O-positron emission tomography study. Headache. 2012; 52: 863-864.
25. Holland P, Goadsby PJ,. The hypothalamic orexinergic system: Pain and primary headaches. Headache. 2007; 47: 951-962.
26. Bolay H, Reuter U, Dunn AK, Huang Z, Boas DA, Moskowitz MA,. Intrinsic brain activity triggers trigeminal meningeal afferents in a migraine model. Nature Medicine. 2002; 8: 136-142.
27. Akcali D, Sayin A, Sara Y, Bolay H,. Does single cortical spreading depression elicit pain behaviour in freely moving rats? Cephalalgia. 2010; 30: 1195-1206.
28. Lipton RB, Dodick DW, Silberstein SD, et al. Single-pulse transcranial magnetic stimulation for acute treatment of migraine with aura: A randomised, double-blind, parallel-group, sham-controlled trial. Lancet Neurol. 2010; 9: 373-380.
29. Hansen JM, Lipton R, Dodick D, et al. Migraine headache is present in the aura phase-a prospective study. Neurology. 2012; 79: 2044-2049.
30. Olesen J, Friberg L, Olsen TS, et al. Timing and topography of cerebral blood flow, aura, and headache during migraine attacks. Ann Neurol. 1990; 28: 791-798.
31. Bereczki D, Kollar J, Kozak N, et al. Cortical spreading edema in persistent visual migraine aura. Headache. 2008; 48: 1226-1229.
32. Cao Y, Welch KM, Aurora S, Vikingstad EM,. Functional MRI-BOLD of visually triggered headache in patients with migraine. Arch Neurol. 1999; 56: 548-554.
33. Chalaupka FD,. Reversible imaging abnormalities consistent with CSD during migraine without aura attack. Headache. 2008; 48: 1229-1232.
34. Cutrer FM, Sorensen AG, Weisskoff RM, et al. Perfusion-weighted imaging defects during spontaneous migrainous aura. Ann Neurol. 1998; 43: 25-31.
35. Dreier JP, Jurkat-Rott K, Petzold GC, et al. Opening of the blood-brain barrier preceding cortical edema in a severe attack of FHM type II. Neurology. 2005; 64: 2145-2147.
36. Flavio Devetag C,. Reversible imaging abnormalities consistent with CSD during migraine without aura attack. Headache. 2008; 48: 1229-1232.
37. Gomez-Choco M, Capurro S, Obach V,. Migraine with aura associated with reversible sulcal hyperintensity in FLAIR. Neurology. 2008; 70: 2416-2418.
38. Hadjikhani N, Sanchez del Rio M, Wu O, et al. Mechanisms of migraine aura revealed by functional MRI in human visual cortex. Proc Natl Acad Sci U S A. 2001; 98: 4687-4692.
39. Jager HR, Giffin NJ, Goadsby PJ,. Diffusion- and perfusion-weighted MR imaging in persistent migrainous visual disturbances. Cephalalgia. 2005; 25: 323-332.
40. MacClellan LR, Giles W, Cole J, et al. Probable migraine with visual aura and risk of ischemic stroke: The stroke prevention in young women study. Stroke. 2007; 38: 2438-2445.
41. Pollock JM, Deibler AR, Burdette JH, et al. Migraine associated cerebral hyperperfusion with arterial spin-labeled MR imaging. AJNR Am J Neuroradiol. 2008; 29: 1494-1497.
42. Resnick S, Reyes-Iglesias Y, Carreras R, Villalobos E,. Migraine with aura associated with reversible MRI abnormalities. Neurology. 2006; 66: 946-947.
43. Sanchez del Rio M, Bakker D, Wu O, et al. Perfusion weighted imaging during migraine: Spontaneous visual aura and headache. Cephalalgia. 1999; 19: 701-707.
44. Smith M, Cros D, Sheen V,. Hyperperfusion with vasogenic leakage by fMRI in migraine with prolonged aura. Neurology. 2002; 58: 1308-1310.
45. Welch KM, Cao Y, Aurora S, Wiggins G, Vikingstad EM,. MRI of the occipital cortex, red nucleus, and substantia nigra during visual aura of migraine. Neurology. 1998; 51: 1465-1469.
46. Guedj E, Belenotti P, Serratrice J, et al. Partially reversible cortical metabolic dysfunction in familial hemiplegic migraine with prolonged aura. Headache. 2010; 50: 872-877.
47. Hansen JM, Schytz HW, Larsen VA, Iversen HK, Ashina M,. Hemiplegic migraine aura begins with cerebral hypoperfusion: Imaging in the acute phase. Headache. 2011; 51: 1289-1296.
48. Iizuka T, Takahashi Y, Sato M, et al. Neurovascular changes in prolonged migraine aura in FHM with a novel ATP1A2 gene mutation. J Neurol Neurosurg Psychiatry. 2012; 83: 205-212.
49. Lanfranconi S, Corti S, Bersano A, et al. Aphasic and visual aura with increased vasogenic leakage: An atypical migrainosus status. J Neurol Sci. 2009; 285: 227-229.
50. Miller C, Goldberg MF,. Susceptibility-weighted imaging and computed tomography perfusion abnormalities in diagnosis of classic migraine. Emerg Radiol. 2012; 19: 565-569.
51. Mourand I, Menjot de Champfleur N, Carra-Dalliere C, et al. Perfusion-weighted MR imaging in persistent hemiplegic migraine. Neuroradiology. 2012; 54: 255-260.
52. Nieuwkamp DJ, van der Schaaf IC, Biessels GJ,. Migraine aura presenting as dysphasia with global cognitive dysfunction and abnormalities on perfusion CT. Cephalalgia. 2010; 30: 1007-1009.
53. Wolf ME, Held VE, Forster A, et al. Pearls & oysters: Dynamics of altered cerebral perfusion and neurovascular coupling in migraine aura. Neurology. 2011; 77: e127-e128.
54. Dinia L, Roccatagliata L, Bonzano L, Finocchi C, Del Sette M,. Diffusion MRI during migraine with aura attack associated with diagnostic microbubbles injection in subjects with large PFO. Headache. 2007; 47: 1455-1456.
55. Gutschalk A, Kollmar R, Mohr A, et al. Multimodal functional imaging of prolonged neurological deficits in a patient suffering from familial hemiplegic migraine. Neurosci Lett. 2002; 332: 115-118.
56. Wolf ME, Jager T, Bazner H, Hennerici M,. Changes in functional vasomotor reactivity in migraine with aura. Cephalalgia. 2009; 29: 1156-1164.
57. Dreier JP, Major S, Manning A, et al. Cortical spreading ischaemia is a novel process involved in ischaemic damage in patients with aneurysmal subarachnoid haemorrhage. Brain. 2009; 132: 1866-1881.
58. Schoonman GG, van der Grond J, Kortmann C, van der, Geest RJ, Terwindt GM, Ferrari MD,. Migraine headache is not associated with cerebral or meningeal vasodilatation-a 3T magnetic resonance angiography study. Brain. 2008; 131: 2192-2200.
59. Nagata E, Moriguchi H, Takizawa S, Horie T, Yanagimachi N, Takagi S,. The middle meningial artery during a migraine attack: 3T magnetic resonance angiography study. Intern Med. 2009; 48: 2133-2135.
60. Asghar MS, Hansen AE, Amin FM, et al. Evidence for a vascular factor in migraine. Ann Neurol. 2011; 69: 635-645.
61. Schytz HW, Schoonman GG, Ashina M,. What have we learnt from triggering migraine? Curr Opin Neurol. 2010; 23: 259-265.
62. Antonova M, Wienecke T, Olesen J, Ashina M,. Prostaglandin E2 induces immediate migraine-like attack in migraine patients without aura. Cephalalgia. 2012; 32: 822-833.
63. Noseda R, Kainz V, Jakubowski M, et al. A neural mechanism for exacerbation of headache by light. Nat Neurosci. 2010; 13: 239-245.
64. Denuelle M, Boulloche N, Payoux P, Fabre N, Trotter Y, Geraud G,. A PET study of photophobia during spontaneous migraine attacks. Neurology. 2011; 76: 213-218.
65. Burstein R, Jakubowski M, Garcia-Nicas E, et al. Thalamic sensitization transforms localized pain into widespread allodynia. Ann Neurol. 2010; 68: 81-91.
66. Färkkila M, Diener HC, Géraud G, et al. Efficacy and tolerability of lasmiditan, a new oral 5-HT1F receptor agonist for the acute treatment of migraine: A phase II randomised, placebo-controlled, parallel-group dose ranging study. Lancet Neurol. 2012; 11: 405-413.
67. Ferrari MD, Farkkila M, Reuter U, et al. Acute treatment of migraine with the selective 5-HT1F receptor agonist lasmiditan-a randomised proof-of-concept trial. Cephalalgia. 2010; 30: 1170-1178.
68. Nelson DL, Phebus LA, Johnson KW, et al. Preclinical pharmacological profile of the selective 5-HT1F receptor agonist lasmiditan. Cephalalgia. 2010; 30: 1159-1169.
69. Goadsby PJ, Classey JD,. Evidence for serotonin (5-HT)1B, 5-HT1D and 5-HT1F receptor inhibitory effects on trigeminal neurons with craniovascular input. Neuroscience. 2003; 122: 491-498.
70. Demarquay G, Lothe A, Royet JP, et al. Brainstem changes in 5-HT1A receptor availability during migraine attack. Cephalalgia. 2011; 31: 84-94.
71. Goadsby PJ, Dodick DW, Almas M, et al. Treatment-emergent CNS symptoms following triptan therapy are part of the attack. Cephalalgia. 2007; 27: 254-262.
72. Denuelle M, Fabre N, Payoux P, Chollet F, Geraud G,. Posterior cerebral hypoperfusion in migraine without aura. Cephalalgia. 2008; 28: 856-862.
73. Boulloche N, Denuelle M, Payoux P, Fabre N, Trotter Y, Geraud G,. Photophobia in migraine: An interictal PET study of cortical hyperexcitability and its modulation by pain. J Neurol Neurosurg Psychiatry. 2010; 81: 978-984.
74. Afridi SK, Matharu MS, Lee L, et al. A PET study exploring the laterality of brainstem activation in migraine using glyceryl trinitrate. Brain. 2005; 128: 932-939.